Sho Sugawara

Sho Sugawara

Auto-generated profile, based on publicly available information

Sho Sugawara

Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2025 in Nature Communications
Verified
Journal Article
Open access
TLTZE MUN LOO
TZE MUN LOO
XZXiangyu Zhou
Xiangyu Zhou
YTYoko Tanaka
Yoko Tanaka
SSSho Sugawara
Sho Sugawara
SYShota Yamauchi
Shota Yamauchi
ATAkiko Takahashi
Akiko Takahashi
Senescent cells, characterized by irreversible cell cycle arrest and inflammatory factor secretion, promote various age-related pathologies. Senescent cells exhibit resistance to ferroptosis, a form of iron-dependent cell death; however, the underlying mechanisms remain unclear. Here, we discovered that lysosomal acidity was crucial for lipid peroxidation and ferroptosis induction by cystine deprivation. In senescent cells, lysosomal alkalinization causes the aberrant retention of ferrous iron in lysosomes, resulting in resistance to ferroptosis. Treatment with the V-ATPase activator EN6 restored lysosomal acidity and ferroptosis sensitivity in senescent cells. A similar ferroptosis resistance mechanism involving lysosomal alkalinization was observed in pancreatic cancer cell lines. EN6 treatment prevented pancreatic cancer development in xenograft and Kras mutant mouse models. Our findings reveal a link between lysosomal dysfunction and the regulation of ferroptosis, suggesting a therapeutic strategy for the treatment of age-related diseases.

28 December 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
SSSho Sugawara
Sho Sugawara
RORyo Okada
Ryo Okada
TLTze Mun Loo
Tze Mun Loo
HTHisamichi Tanaka
Hisamichi Tanaka
KMKenichi Miyata
Kenichi Miyata
ATAkiko Takahashi
Akiko Takahashi
Cellular senescence caused by oncogenic stimuli is associated with the development of various age-related pathologies through the senescence-associated secretory phenotype (SASP). SASP is mediated by the activation of cytoplasmic nucleic acid sensors. However, the molecular mechanism underlying the accumulation of nucleotide ligands in senescent cells is unclear. In this study, we revealed that the expression of RNaseH2A, which removes ribonucleoside monophosphates (rNMPs) from the genome, is regulated by E2F transcription factors, and it decreases during cellular senescence. Residual rNMPs cause genomic DNA fragmentation and aberrant activation of cytoplasmic nucleic acid sensors, thereby provoking subsequent SASP factor gene expression in senescent cells. In addition, RNaseH2A expression was significantly decreased in aged mouse tissues and cells from individuals with Werner syndrome. Furthermore, RNaseH2A degradation using the auxin-inducible degron system induced the accumulation of nucleotide ligands and induction of certain tumourigenic SASP-like factors, promoting the metastatic properties of colorectal cancer cells. Our results indicate that RNaseH2A downregulation provokes SASP through nucleotide ligand accumulation, which likely contributes to the pathological features of senescent, progeroid, and cancer cells.

29 January 2026 in Nature Aging
Verified
Journal Article
Open access
PDF file
MWMasahiro Wakita
Masahiro Wakita
KIKoyu Ito
Koyu Ito
KFKaho Fujii
Kaho Fujii
DSDai Sakamoto
Dai Sakamoto
TMTakumi Mikawa
Takumi Mikawa
EHEiji Hara
Eiji Hara
Cellular senescence contributes to aging and disease, and senolytic drugs that selectively eliminate senescent cells hold therapeutic promise. Although over 20 candidates have been reported, their relative efficacies remain unclear. Here we systematically compared 21 senolytic agents using a senolytic specificity index, identifying the Bcl-2 inhibitor ABT263 and the BET inhibitor ARV825 as most effective senolytics across fibroblast and epithelial senescence models. However, even upon extended treatment with these most potent senolytics, a proportion of senescent cells remained viable. We found that senolytic resistance was driven by maintenance of mitochondrial integrity through V-ATPase-mediated clearance of damaged mitochondria. Imposing mitochondrial stress via metabolic workload enhanced the senolytic efficacies of ABT263 and ARV825 in vitro, and in mouse models, ketogenic diet adoption or SGLT2 inhibition similarly potentiated ABT263-induced and ARV825-induced senolysis, reducing metastasis and tumor growth. These findings suggest that mitochondrial quality control is a key determinant of resistance to ABT263-induced and ARV825-induced senolysis, providing a possible framework for rational combination senotherapies.

3 April 2026 in EMBO Reports
Verified
Journal Article
Open access
PDF file
SKShimpei Kawamoto
Shimpei Kawamoto
HHHaruki Horiguchi
Haruki Horiguchi
DTDaisuke Torigoe
Daisuke Torigoe
MWMasahiro Wakita
Masahiro Wakita
KIKoyu Ito
Koyu Ito
EHEiji Hara
Eiji Hara
The discovery of the senescence-associated secretory phenotype (SASP) has reshaped our understanding of cellular senescence, shifting its role from a solely tumor-suppressive mechanism to a potential driver of chronic inflammation and age-related diseases. Accordingly, senolytic drugs, which selectively eliminate senescent cells, have garnered considerable interest due to promising preclinical studies. However, concerns remain regarding the reproducibility and generalizability of these findings. In this cross-laboratory study, we rigorously tested the senolytic efficacy of a GLS1 inhibitor and an anti-PD-1 antibody—agents previously reported to reduce the burden of p16 INK4a -positive senescent cells and improve health outcomes in aged mice. Contrary to earlier reports, our study demonstrates that neither GLS1 inhibition nor PD-1 blockade significantly reduced p16 INK4a -positive cell burden or improved aging-related health parameters. Although we do not seek to discredit prior work, our results underscore the need for rigorous design, standardized protocols, and independent validation to ensure reliable senolytics before clinical translation.

30 December 2025 in Communications Biology
Verified
Journal Article
Open access
SSSho Sugawara
Sho Sugawara
RORyo Okada
Ryo Okada
TLTze Mun Loo
Tze Mun Loo
HTHisamichi Tanaka
Hisamichi Tanaka
KMKenichi Miyata
Kenichi Miyata
ATAkiko Takahashi
Akiko Takahashi